TY  - JOUR
T1  - Freedom to innovate: The perils of centralized medical research
AU  - Huesch M, Lakdawalla D
Y1  - 2012/11/26
N1  - 10.1001/2013.jamainternmed.53
JO  - Archives of Internal Medicine
SP  - 1692
EP  - 1693
VL  - 172
IS  - 21
N2  - 
Prasad and colleagues1 present a viewpoint on the evolution of medical practices, with a striking claim and a problematic recommendation. They claim that there is “no incentive for companies to test scientific questions, which may only diminish market demand.”1(p957) Their proffered solution is that “trial funding should move away from industry-sponsored studies and toward a model where funds are pooled into a central and impartial agency that decides what trials to administer.”1(p957)

SN  - 0003-9926
M3  - doi: 10.1001/2013.jamainternmed.53
UR  - http://dx.doi.org/10.1001/2013.jamainternmed.53
ER  -